Yangtze River Pharmaceutical Group To Invest RMB 300 Million In Innovation Projects
This article was originally published in PharmAsia News
Executive Summary
Yangtze River Pharmaceutical Group will invest RMB 300 million to carry out innovative R&D projects this year. The group aims to secure a total of 39 production licenses including nine for class I new drugs, as well as 30 clinical trial permits. It is also filing applications for 24 preclinical research projects. At present, the firm has more than 100 new products under development: new drug iguratimod has entered Phase III trials; yonkenafil will soon complete its Phase I trial; MB-1C is on track to preclinical research; and forsythiaside will receive permission for clinical trials. With focus on establishing an innovation platform, the company is setting up the Jiangsu (Taizhou) New Medicine Research Institute, a national laboratory of pharmaceutical formulation emphasizing new technology and a national engineering research center for TCM pharmaceutical technology. (Click here for more - Chinese Language)
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.